Browse the evidence

In patients with advanced chronic liver disease (ACLD), achieving >10% body weight loss through therapeutic lifestyle interventions significantly reduces portal hypertension and improves survival, although this magnitude of weight loss is difficult to sustain long-term.

For ACLD patients, aiming for >10% weight loss via diet and exercise can significantly lower portal pressure and improve survival. However, this is hard to maintain; consider medical weight loss aids if lifestyle changes alone fail to sustain the loss.

New generation obesity medications (GLP-1/GIP agonists) achieve mean weight loss of 15–25% over 68–72 weeks, narrowing the efficacy gap between medical and surgical management of obesity.

New GLP-1/GIP medications like semaglutide (2.4mg weekly) and tirzepatide are highly effective, producing 15-25% weight loss over ~1.5 years. This efficacy is now comparable to surgery, making medication a primary, not just secondary, option for obesity treatment.

High body mass index (BMI) and visceral adiposity are strong independent risk factors for the development and progression of chronic kidney disease (CKD), end-stage renal disease (ESRD), and obesity-related glomerulopathy (ORG).

Maintaining a healthy weight is one of the most effective ways to protect your kidneys. High body weight puts direct mechanical and hormonal stress on your kidneys, increasing the risk of kidney failure. If you are overweight, even modest weight loss through diet and exercise can significantly lower your risk of developing kidney disease or slow its progression.

Poor glycemic control exacerbates dyslipidemia in diabetes by increasing hepatic VLDL production and decreasing HDL levels, while improvements in glycemic control can reverse these lipid abnormalities.

For people with diabetes, keeping blood sugar levels in range is important, but it is not enough to protect your heart. Even if your A1C is good, you likely still have abnormal cholesterol levels, specifically high triglycerides and low HDL. This is because diabetes changes how your liver processes fats. You need to monitor your lipid profile separately and likely take medication (like statins) to manage cardiovascular risk, regardless of how well your blood sugar is controlled.

A Body Shape Index (ABSI) is associated with incident cardiovascular disease, with the highest risk observed in individuals with high ABSI combined with high RCII.

For adults over 45, monitoring your Body Shape Index (ABSI) alongside your cholesterol and inflammation levels (RCII) provides a more accurate assessment of heart disease risk than weight alone. If you have a high ABSI and high RCII, you are in a high-risk subgroup that may benefit from intensified lifestyle interventions.

Ultra rapid lispro (URLi) administered as a bolus with basal insulin improves postprandial glucose excursions (PPGE) after breakfast more effectively than standard insulin lispro in adults with type 2 diabetes, while maintaining non-inferior HbA1c reduction and similar safety profiles regarding hypoglycemia and weight gain.

If you have Type 2 Diabetes and struggle with high blood sugar after meals, especially breakfast, ask your doctor about Ultra Rapid Lispro (URLi). It is taken exactly like your current rapid-acting insulin (just before eating) but absorbs faster to better match your food. This can significantly reduce the sharp blood sugar spikes after breakfast without increasing your risk of low blood sugar or weight gain compared to standard insulin lispro.

Metformin is the preferred initial oral hypoglycemic monotherapy for type 2 diabetes due to its efficacy, safety, and low risk of hypoglycemia and weight gain.

Start with metformin as your first medication if lifestyle changes alone aren't enough. It is the standard because it works well, is safe long-term, and rarely causes low blood sugar or weight gain. If your blood sugar isn't controlled, your doctor will add another medication.

If metformin is contraindicated or not tolerated, other oral hypoglycemic agents (DPP4 inhibitors, SGLT2 inhibitors, Sulfonylureas, etc.) can be used as initial monotherapy based on clinical situation.

If you can't take metformin, your doctor will choose another medication based on your specific health needs, such as kidney function or heart risk. Options include DPP4 inhibitors, SGLT2 inhibitors, or others.

Among pharmacotherapies, Semaglutide 2.4 mg and Orlistat have the most favorable safety/tolerability profiles, while Liraglutide 3.0 mg has the least tolerability, and Tirzepatide has intermediate tolerability.

When choosing a weight loss medication, be aware that tolerability varies. Semaglutide and Orlistat tend to be better tolerated, while Liraglutide may cause more side effects. Tirzepatide, despite its high efficacy, has intermediate tolerability, meaning you might experience more side effects than with Semaglutide or Orlistat.

Improvements in insulin sensitivity (HOMA-IR) and intrahepatic lipid content during caloric restriction are transient and not maintained during the weight maintenance phase, unlike other cardiometabolic markers.

Be aware that while caloric restriction improves insulin sensitivity during the weight loss phase, this specific benefit may not persist once you stop losing weight, even if you maintain the lower calorie intake. Other cardiovascular benefits, like lower blood pressure and better cholesterol, do persist. This suggests that maintaining a healthy weight and diet is crucial, but you might need additional strategies (like exercise or specific dietary components) to sustain insulin sensitivity improvements long-term.

Performing resistance training in an energy deficit impairs lean mass gains compared to training in energy balance, but does not impair strength gains.

If you are trying to lose weight while lifting weights, expect to get stronger but not necessarily bigger. A 500 kcal daily deficit will likely stop you from gaining lean mass, but you will still improve your strength. To maximize muscle growth, you must avoid prolonged energy deficits.

Meal replacements improve satiety and reduce cravings during caloric restriction through mechanisms like stimulus narrowing and ketosis, despite expected hormonal changes.

You might worry that eating less will make you hungry, but using meal replacements can actually help control hunger. By limiting food choices (stimulus narrowing) and potentially inducing ketosis, MRs can reduce cravings and make sticking to a diet easier.

Continued treatment with Tirzepatide maintains significant weight loss and cardiometabolic improvements, whereas discontinuation leads to partial weight regain and loss of benefits, demonstrating that long-term adherence is required to sustain outcomes.

If you are using Tirzepatide for weight loss, understand that it is a long-term treatment, not a short-term fix. Stopping the medication will likely cause you to regain most of the weight you lost. To keep the weight off, you must continue the medication indefinitely, combined with healthy lifestyle habits, just as you would manage high blood pressure with medication.

Dual GIP/GLP-1 receptor agonism (e.g., tirzepatide) yields superior glycemic control and body weight reduction compared to selective GLP-1 receptor agonists.

For patients with type 2 diabetes seeking maximum glucose and weight reduction, dual GIP/GLP-1 agonists (like tirzepatide) are clinically superior to selective GLP-1 agonists. This represents a shift from previous assumptions that GIP was therapeutically useless in diabetes.

A higher triglyceride-glucose (TyG) index, serving as a surrogate marker for insulin resistance, is significantly associated with increased risks of composite cardiovascular events, cardiovascular mortality, myocardial infarction, stroke, and incident type 2 diabetes.

Your risk for heart disease and diabetes is closely linked to your insulin resistance, which can be estimated using a simple calculation from your fasting triglyceride and glucose levels. This risk is not uniform; it is significantly higher for people living in low- and middle-income countries. Regular monitoring of these markers can help identify those at high risk for cardiovascular events and diabetes, allowing for earlier intervention.

Early time-restricted feeding (eTRF) reduces appetite and increases fat oxidation but does not significantly alter 24-hour energy expenditure in humans.

If you try eating all your meals between 8 am and 2 pm, you likely won't burn significantly more calories than usual. However, you will likely feel less hungry and more full throughout the day because your hunger hormones (ghrelin) are better regulated. This makes it easier to eat less without feeling deprived, which is the actual mechanism for weight loss.

Consumption of flavonoid-rich foods (cocoa, tea, berries) produces small but measurable improvements in blood pressure, endothelial function, and insulin resistance, mediated by enhanced nitric oxide bioavailability and AMPK activation.

Incorporate flavonoid-rich foods like dark chocolate (cocoa), tea, and berries into your daily diet. You do not need large quantities; even small amounts (e.g., ~30 kcal/d of dark chocolate) can contribute to lower blood pressure and better vascular health. Focus on consistency rather than high doses of supplements.

GLP-1 receptor agonists exhibit significant inter-individual variability in weight loss, with early responders (>=4% loss at week 16) predicting superior long-term outcomes.

If you start a GLP-1 agonist (like Ozempic or Wegovy) and don't lose at least 4% of your body weight by week 16, you are statistically likely to be a 'non-responder' with only ~3% total loss. However, early weight loss is a strong predictor of success. If you are not losing weight early, discuss with your doctor whether to continue for metabolic benefits or switch therapies, as stopping rules are often built into prescriptions.

Higher protein intakes (above RDA) do not negatively impact bone mineral density and may actually protect against osteoporosis and hip fractures by increasing calcium bioavailability and IGF-1 release.

You do not need to worry that eating more protein will weaken your bones. In fact, getting enough protein helps your body absorb calcium better and may lower your risk of hip fractures, especially if you are getting enough calcium in your diet.

High consumption of white rice (≥450 g/day) is associated with an increased risk of incident type 2 diabetes, with the strongest association observed in South Asian populations.

If you eat large amounts of white rice (more than 3 cups cooked per day), your risk of developing type 2 diabetes increases, especially if you are of South Asian descent. To reduce this risk without necessarily giving up rice, try switching to brown rice, choosing high-fiber white rice varieties, or adding legumes (beans, lentils) to your rice meals to lower the glycemic impact. Be aware that in China, this specific risk was not statistically significant, suggesting regional or varietal differences.

SGLT2 inhibitors lower HbA1c by 0.6-0.8% without increasing hypoglycemia risk when used as monotherapy, but require dose adjustment of insulin/secretagogues when combined.

SGLT2 inhibitors effectively lower blood sugar (HbA1c) by about 0.6-0.8% without causing low blood sugar on their own. If you are also taking insulin or sulfonylureas, your doctor may lower your dose of those medications to prevent hypoglycemia. This makes them a safer option for many patients compared to older drugs.

Time-restricted feeding (TRF) with early or midday timing improves insulin sensitivity and cardiometabolic health markers more effectively than late TRF, independent of caloric restriction.

If you practice Time-Restricted Feeding, try to eat your meals earlier in the day (e.g., 8 AM to 2 PM or 10 AM to 6 PM). This timing aligns with your body's natural circadian rhythm and has been shown to improve insulin sensitivity and blood pressure more effectively than eating the same calories later in the evening. You do not need to restrict calories strictly; simply shifting your eating window earlier can yield metabolic benefits.

Intermittent Fasting (IF) regimens (5:2, ADF, ADMF, TRF) produce weight loss comparable to daily caloric restriction (CR), but may offer superior insulin-sensitizing benefits independent of weight loss.

If you are choosing between Intermittent Fasting and daily calorie restriction for weight loss, know that both methods are equally effective for losing weight. However, IF may offer extra benefits for your metabolic health, such as better insulin sensitivity, which might be important if you have prediabetes or metabolic syndrome. Choose the method you can sustain long-term.

High body mass index (BMI) is a strong independent risk factor for the development and progression of chronic kidney disease (CKD), primarily driven by compensatory glomerular hyperfiltration and increased intraglomerular pressure.

Maintaining a healthy weight is one of the most effective ways to protect your kidneys. Excess body weight forces your kidneys to work harder (hyperfiltration), which can cause long-term damage. Focus on sustainable lifestyle changes like balanced nutrition and regular physical activity to manage weight, especially if you have a family history of kidney issues or high blood pressure.